[go: up one dir, main page]

SI3663296T1 - Postopek za pripravo spojin, uporabnih za zdravljenje spinalne mišične atrofije - Google Patents

Postopek za pripravo spojin, uporabnih za zdravljenje spinalne mišične atrofije

Info

Publication number
SI3663296T1
SI3663296T1 SI201531952T SI201531952T SI3663296T1 SI 3663296 T1 SI3663296 T1 SI 3663296T1 SI 201531952 T SI201531952 T SI 201531952T SI 201531952 T SI201531952 T SI 201531952T SI 3663296 T1 SI3663296 T1 SI 3663296T1
Authority
SI
Slovenia
Prior art keywords
preparation
compounds useful
muscular atrophy
spinal muscular
treating spinal
Prior art date
Application number
SI201531952T
Other languages
English (en)
Inventor
Hasane Ratni
Luke Green
Nikolai A. Naryshkin
Marla L. Weetall
Original Assignee
F. Hoffmann-La Roche Ag
Ptc Therapeutics, Inc.
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Family has litigation
First worldwide family litigation filed litigation Critical https://patents.darts-ip.com/?family=53175048&utm_source=google_patent&utm_medium=platform_link&utm_campaign=public_patent_search&patent=SI3663296(T1) "Global patent litigation dataset” by Darts-ip is licensed under a Creative Commons Attribution 4.0 International License.
Application filed by F. Hoffmann-La Roche Ag, Ptc Therapeutics, Inc. filed Critical F. Hoffmann-La Roche Ag
Publication of SI3663296T1 publication Critical patent/SI3663296T1/sl

Links

Classifications

    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D487/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00
    • C07D487/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, not provided for by groups C07D451/00 - C07D477/00 in which the condensed system contains two hetero rings
    • C07D487/04—Ortho-condensed systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/50—Pyridazines; Hydrogenated pyridazines
    • A61K31/5025—Pyridazines; Hydrogenated pyridazines ortho- or peri-condensed with heterocyclic ring systems
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61K—PREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00—Medicinal preparations containing organic active ingredients
    • A61K31/33—Heterocyclic compounds
    • A61K31/395—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/495—Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with two or more nitrogen atoms as the only ring heteroatoms, e.g. piperazine or tetrazines
    • A61K31/505—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim
    • A61K31/519—Pyrimidines; Hydrogenated pyrimidines, e.g. trimethoprim ortho- or peri-condensed with heterocyclic rings
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P21/00—Drugs for disorders of the muscular or neuromuscular system
    • A61P21/02—Muscle relaxants, e.g. for tetanus or cramps
    • A—HUMAN NECESSITIES
    • A61—MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61P—SPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P25/00—Drugs for disorders of the nervous system
    • A61P25/28—Drugs for disorders of the nervous system for treating neurodegenerative disorders of the central nervous system, e.g. nootropic agents, cognition enhancers, drugs for treating Alzheimer's disease or other forms of dementia
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D471/00—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02—Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04—Ortho-condensed systems
    • C—CHEMISTRY; METALLURGY
    • C07—ORGANIC CHEMISTRY
    • C07D—HETEROCYCLIC COMPOUNDS
    • C07D519/00—Heterocyclic compounds containing more than one system of two or more relevant hetero rings condensed among themselves or condensed with a common carbocyclic ring system not provided for in groups C07D453/00 or C07D455/00

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Medicinal Chemistry (AREA)
  • General Health & Medical Sciences (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Veterinary Medicine (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Bioinformatics & Cheminformatics (AREA)
  • Neurology (AREA)
  • Engineering & Computer Science (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • General Chemical & Material Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Physical Education & Sports Medicine (AREA)
  • Neurosurgery (AREA)
  • Biomedical Technology (AREA)
  • Orthopedic Medicine & Surgery (AREA)
  • Epidemiology (AREA)
  • Hospice & Palliative Care (AREA)
  • Psychiatry (AREA)
  • Pain & Pain Management (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Acyclic And Carbocyclic Compounds In Medicinal Compositions (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Steroid Compounds (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
SI201531952T 2014-05-15 2015-05-11 Postopek za pripravo spojin, uporabnih za zdravljenje spinalne mišične atrofije SI3663296T1 (sl)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US201461993839P 2014-05-15 2014-05-15
EP19200058.6A EP3663296B1 (en) 2014-05-15 2015-05-11 Process for the preparation of compounds useful for treating spinal muscular atrophy

Publications (1)

Publication Number Publication Date
SI3663296T1 true SI3663296T1 (sl) 2023-08-31

Family

ID=53175048

Family Applications (2)

Application Number Title Priority Date Filing Date
SI201531021T SI3143025T1 (sl) 2014-05-15 2015-05-11 Spojine za zdravljenje spinalne mišične atrofije
SI201531952T SI3663296T1 (sl) 2014-05-15 2015-05-11 Postopek za pripravo spojin, uporabnih za zdravljenje spinalne mišične atrofije

Family Applications Before (1)

Application Number Title Priority Date Filing Date
SI201531021T SI3143025T1 (sl) 2014-05-15 2015-05-11 Spojine za zdravljenje spinalne mišične atrofije

Country Status (36)

Country Link
US (1) US9969754B2 (sl)
EP (3) EP3663296B1 (sl)
JP (1) JP6236173B2 (sl)
KR (2) KR102256013B1 (sl)
CN (1) CN106459092B (sl)
AR (2) AR100442A1 (sl)
AU (1) AU2015261046C1 (sl)
BR (1) BR112016026205B1 (sl)
CA (1) CA2948561C (sl)
CL (1) CL2016002836A1 (sl)
CR (1) CR20160518A (sl)
DK (1) DK3143025T3 (sl)
EA (2) EA035068B1 (sl)
ES (2) ES2761423T3 (sl)
FR (1) FR21C1039I2 (sl)
HR (2) HRP20230637T1 (sl)
HU (2) HUE046491T2 (sl)
IL (2) IL248653B (sl)
LT (1) LTC3143025I2 (sl)
MA (2) MA51988A (sl)
MX (1) MX371050B (sl)
MY (1) MY174284A (sl)
NL (1) NL301128I2 (sl)
NO (2) NO2021035I1 (sl)
NZ (1) NZ725008A (sl)
PE (1) PE20170128A1 (sl)
PH (1) PH12016502081B1 (sl)
PL (2) PL3143025T3 (sl)
PT (1) PT3143025T (sl)
RS (1) RS59718B1 (sl)
SG (1) SG11201609497TA (sl)
SI (2) SI3143025T1 (sl)
TW (1) TWI667239B (sl)
UA (1) UA119670C2 (sl)
WO (1) WO2015173181A1 (sl)
ZA (1) ZA201607026B (sl)

Families Citing this family (40)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
EA037123B1 (ru) 2012-02-10 2021-02-09 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
JP6689197B2 (ja) 2013-08-19 2020-04-28 エフ・ホフマン−ラ・ロシュ・アクチェンゲゼルシャフト スクリーニング方法
US10882868B2 (en) * 2014-05-15 2021-01-05 Hoffmann-La Roche Inc. Compounds for treating spinal muscular atrophy
EP3298017B1 (en) 2015-05-20 2019-08-14 H. Hoffnabb-La Roche Ag Compounds for treating spinal muscular atrophy
EP3310169B1 (en) 2015-05-30 2023-05-17 PTC Therapeutics, Inc. Methods for modulating rna splicing
BR112018009281B1 (pt) 2015-11-12 2023-10-31 F. Hoffmann-La Roche Ag Composições para tratar atrofia muscular espinhal e seu uso
AR106652A1 (es) * 2015-11-12 2018-02-07 Hoffmann La Roche Compuestos para tratar la esclerosis lateral amiotrófica
JP6872550B2 (ja) 2015-12-10 2021-05-19 エフ．ホフマン−ラ ロシュ アーゲーＦ． Ｈｏｆｆｍａｎｎ−Ｌａ Ｒｏｃｈｅ Ａｋｔｉｅｎｇｅｓｅｌｌｓｃｈａｆｔ 架橋されたピペリジン誘導体
MX382671B (es) 2015-12-10 2025-03-13 Ptc Therapeutics Inc Compuestos para usarse en el tratamiento o mejoramiento de la enfermedad de huntington
JP2019535789A (ja) * 2016-11-28 2019-12-12 ピーティーシー セラピューティクス，インコーポレーテッド Ｒｎａスプライシングを調節する方法
JP7376471B2 (ja) 2017-06-05 2023-11-08 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
CN111372611A (zh) 2017-06-14 2020-07-03 Ptc医疗公司 修饰rna剪接的方法
MX2019015580A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
MX2019015578A (es) 2017-06-28 2020-07-28 Ptc Therapeutics Inc Metodos para tratar la enfermedad de huntington.
MX2020002711A (es) * 2017-09-22 2020-07-20 Hoffmann La Roche Proceso para preparacion de 7-(4,7-diazaespiro[2.5]octan-7-il)-2-( 2,8-dimetilimidazo[1,2-b]piridazin-6-il)pirido[1,2-a]pirimidin-4- ona.
AU2018344402B2 (en) * 2017-10-03 2024-08-29 F. Hoffmann-La Roche Ag New treatment of SMA
JP7399870B2 (ja) 2018-03-27 2023-12-18 ピーティーシー セラピューティクス， インコーポレイテッド ハンチントン病を処置するための化合物
EA202092899A1 (ru) 2018-06-27 2021-05-14 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Гетероарильные соединения для лечения болезни гентингтона
WO2020004594A1 (ja) 2018-06-27 2020-01-02 株式会社リボルナバイオサイエンス 脊髄性筋萎縮症の予防または治療剤
LT3814357T (lt) 2018-06-27 2024-06-25 Ptc Therapeutics, Inc. Heterocikliniai ir heteroarilų junginiai, skirti hantingtono ligos gydymui
US11685746B2 (en) 2018-06-27 2023-06-27 Ptc Therapeutics, Inc. Heteroaryl compounds for treating Huntington's disease
TWI861018B (zh) 2018-10-19 2024-11-11 瑞士商赫孚孟拉羅股份公司 吡啶并[1,2-a]嘧啶-4-酮衍生物之新型式、及調配物及製備方法
EP3982970A1 (en) 2019-06-12 2022-04-20 F. Hoffmann-La Roche AG New treatment of sma
EP4004003A1 (en) 2019-07-31 2022-06-01 Teva Pharmaceuticals International GmbH Solid state forms of risdiplam and process for preparation thereof
WO2021207550A1 (en) * 2020-04-08 2021-10-14 Remix Therapeutics Inc. Compounds and methods for modulating splicing
WO2022048675A1 (zh) * 2020-09-07 2022-03-10 苏州科睿思制药有限公司 Risdiplam晶型及其制备方法和用途
WO2022162107A1 (en) 2021-02-01 2022-08-04 Sandoz Ag Crystalline form of risdiplam
JP2024510487A (ja) * 2021-03-17 2024-03-07 エフ． ホフマン－ラ ロシュ アーゲー 新規なチアジアゾロピリミドン誘導体
CA3212341A1 (en) 2021-03-17 2022-09-22 F. Hoffmann-La Roche Ag New thiazolopyrimidinone derivatives
AU2022237836B2 (en) * 2021-03-18 2024-07-04 F. Hoffmann-La Roche Ag Process for preparing risdiplam
WO2023057404A1 (en) 2021-10-06 2023-04-13 F. Hoffmann-La Roche Ag Novel combined administration
CN118005654A (zh) * 2022-04-18 2024-05-10 深圳市塔吉瑞生物医药有限公司 取代的吡啶并嘧啶酮类化合物及包含该化合物的组合物及其用途
WO2023240236A1 (en) 2022-06-10 2023-12-14 Voyager Therapeutics, Inc. Compositions and methods for the treatment of spinal muscular atrophy related disorders
WO2024069646A1 (en) * 2022-09-26 2024-04-04 Natco Pharma Limited Improved process for the preparation of risdiplam and its intermediates
US20240173325A1 (en) 2022-10-14 2024-05-30 Genentech, Inc. Methods for treating spinal muscular atrophy
CN120530115A (zh) * 2023-01-21 2025-08-22 哈曼菲诺化学有限公司 利司扑兰的制备方法、新型中间体及其制备方法
WO2024218207A1 (en) 2023-04-20 2024-10-24 F. Hoffmann-La Roche Ag Thieno[3,2-b]pyridine derivatives
WO2024251925A1 (en) 2023-06-09 2024-12-12 F. Hoffmann-La Roche Ag Inducible gene expression system
CN117050096A (zh) * 2023-07-17 2023-11-14 杭州诺澳生物医药科技有限公司 一种利司扑兰的制备方法
US20250144031A1 (en) 2023-10-27 2025-05-08 Hoffmann-La Roche Inc. Composition for treating spinal muscular atrophy

Family Cites Families (11)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
ATE232863T1 (de) * 1996-08-06 2003-03-15 Pfizer Substituierte pyrido- oder pyrimidogruppen enthaltende 6,6- oder 6,7-bicyclische derivate
US20100267712A1 (en) 2007-09-27 2010-10-21 The United States of America, as represented by the Secretary, Department of Health and Isoindoline compounds for the treatment of spinal muscular atrophy and other uses
WO2009151546A2 (en) * 2008-05-27 2009-12-17 Ptc Therapeutics, Inc. Methods for treating spinal muscular atrophy
KR20100012134A (ko) * 2008-07-28 2010-02-08 신호열 마우스
US8932818B2 (en) 2008-08-13 2015-01-13 Ptc Therapeutics, Inc. Screening assays for compounds that modulate programmed ribosomal frameshifting
WO2010019326A1 (en) * 2008-08-14 2010-02-18 Cardiac Pacemakers, Inc. Performance assessment and adaptation of an acoustic communication link
USRE47689E1 (en) * 2011-12-30 2019-11-05 Ptc Therapeutics, Inc. Compounds for treating spinal muscular atrophy
CA2862084C (en) * 2012-01-26 2021-05-11 Ptc Therapeutics, Inc. 1h-isochromen-1-one derivatives and compositions thereof for treating spinal muscular atrophy
EA037123B1 (ru) * 2012-02-10 2021-02-09 ПиТиСи ТЕРАПЬЮТИКС, ИНК. Соединения для лечения спинальной мышечной атрофии
US9212209B2 (en) 2012-07-13 2015-12-15 Indiana University Research And Technology Corporation Screening methods for spinal muscular atrophy
BR112018009281B1 (pt) 2015-11-12 2023-10-31 F. Hoffmann-La Roche Ag Composições para tratar atrofia muscular espinhal e seu uso

Also Published As

Publication number Publication date
KR102213740B1 (ko) 2021-02-09
KR20170003687A (ko) 2017-01-09
UA119670C2 (uk) 2019-07-25
JP6236173B2 (ja) 2017-11-22
PE20170128A1 (es) 2017-03-16
IL248653B (en) 2019-11-28
HRP20230637T1 (hr) 2023-09-29
SI3143025T1 (sl) 2020-01-31
CN106459092A (zh) 2017-02-22
LTC3143025I2 (sl) 2023-11-10
MA51988A (fr) 2021-01-20
HUS2100037I1 (hu) 2021-10-28
DK3143025T3 (da) 2019-12-09
EP3663296B1 (en) 2023-05-17
JP2017515863A (ja) 2017-06-15
EP3143025B1 (en) 2019-10-09
CA2948561C (en) 2019-10-22
EA202090486A2 (ru) 2020-06-30
HRP20192159T1 (hr) 2020-02-21
IL270027B (en) 2020-08-31
HUE046491T2 (hu) 2020-03-30
EP3663296A1 (en) 2020-06-10
AU2015261046A1 (en) 2016-10-27
MA39995B1 (fr) 2019-11-29
TW201609738A (zh) 2016-03-16
ZA201607026B (en) 2022-05-25
US20170197990A1 (en) 2017-07-13
PH12016502081A1 (en) 2017-01-09
KR20210014219A (ko) 2021-02-08
EP4241772A3 (en) 2023-11-15
EA201692280A1 (ru) 2018-07-31
PH12016502081B1 (en) 2022-11-23
EP4241772A2 (en) 2023-09-13
CA2948561A1 (en) 2015-11-19
CL2016002836A1 (es) 2017-04-21
RS59718B1 (sr) 2020-01-31
AR100442A1 (es) 2016-10-05
EA035068B1 (ru) 2020-04-23
FR21C1039I1 (sl) 2021-10-15
PL3663296T3 (pl) 2023-08-07
NL301128I2 (nl) 2021-10-25
IL248653A0 (en) 2017-01-31
LTPA2021010I1 (sl) 2021-10-11
BR112016026205A2 (pt) 2017-08-15
BR112016026205A8 (pt) 2021-07-20
CR20160518A (es) 2017-02-21
PT3143025T (pt) 2019-12-03
FR21C1039I2 (fr) 2022-09-02
WO2015173181A1 (en) 2015-11-19
SG11201609497TA (en) 2016-12-29
US9969754B2 (en) 2018-05-15
CN106459092B (zh) 2019-10-15
NO2021035I1 (no) 2021-09-10
TWI667239B (zh) 2019-08-01
AU2015261046C1 (en) 2019-07-25
AU2015261046B2 (en) 2019-04-18
EA202090486A3 (ru) 2020-08-31
PL3143025T3 (pl) 2020-03-31
AR131260A2 (es) 2025-03-05
NL301128I1 (sl) 2021-09-22
KR102256013B1 (ko) 2021-05-26
BR112016026205B1 (pt) 2021-12-07
ES2949660T3 (es) 2023-10-02
MX2016014547A (es) 2017-02-23
NZ725008A (en) 2019-11-29
NO2025038I1 (no) 2025-08-14
EP3143025A1 (en) 2017-03-22
MY174284A (en) 2020-04-01
MX371050B (es) 2020-01-14
ES2761423T3 (es) 2020-05-19

Similar Documents

Publication Publication Date Title
HUS2100037I1 (hu) Vegyületek gerinc eredetû izomsorvadás kezelésére
IL258497A (en) Preparations for the treatment of sma muscular dystrophy
IL279627A (en) A method for treating depression
ZA201706795B (en) Process for the preparation of dicycloplatin
ZA201800869B (en) Continuous process for the treatment of wastewater
AP2016009497A0 (en) Process for the treatment of high sulphate waters
IL248267B (en) A process for preparing converted cycloserines
IL268835B (en) A process for the preparation of 2-cyanoimidazole compounds
IL261277A (en) Combination therapies for treatment of spinal muscular atrophy
IL275480A (en) A process for the preparation of pyrimidinyl-4-aminopyrazole compounds
IL247443B (en) Process for the preparation of 5-fluorotryptophol
SI3207009T1 (sl) Postopek priprave halo substituiranih benzenov
IL251202A0 (en) A process for the preparation of halo-modified trifluoroacetophenones
PL2937084T3 (pl) Sposób leczenia hipercholesterolemii
IL267059A (en) A preparation for the treatment of osteoarthritis
ZA201701099B (en) Process for the preparation of aromatic compounds
GB201501446D0 (en) Improved process for the treatment of high sulphate waters
GB201418513D0 (en) Compounds for the treatment of muscular dystrophy having improved bioavailability